CXCR1 and lip and oral cavity carcinoma: In studies using the MOC1 (murine oral cancer 1) model, single-agent treatment with either the CXCR1/2 antagonist, SX-682, or PD1-mAb had no significant effect on tumor growth or survival, but combination treatment with SX-682 and PD1-mAb significantly reduced tumor growth, improved survival, and caused complete tumor rejection in 20% of mice [58].